Review



β lapachone  (MedChemExpress)


Bioz Verified Symbol MedChemExpress is a verified supplier
Bioz Manufacturer Symbol MedChemExpress manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 94

    Structured Review

    MedChemExpress β lapachone
    β Lapachone, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 11 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/%CE%B2+lapachone/%CE%B2-Lapachone/pm40103499-253-6-10
    Average 94 stars, based on 11 article reviews
    β lapachone - by Bioz Stars, 2026-11
    94/100 stars

    Images

    Related Articles

    Expressing:


    Article Title: RNA binding protein NKAP protects glioblastoma cells from ferroptosis by promoting SLC7A11 mRNA splicing in an m 6 A-dependent manner
    Article Snippet: Each group of cells were treated with compounds including 10 μM erastin (HY-15763, MCE, USA), 100 μM iFSP1 (HY-136057, MCE, USA), 500 μM SAS (HY-14655, MCE, USA), 2.5 μM rotenone (HY-B1756, MCE, USA), 300 nM 17-DMAG (HY-10389, MCE, USA), 1.5 μM staurosporine (HY-15141, MCE, USA), 200 μM TMZ (HY-17364, MCE, USA), 2 μM β-lapachone (HY-13555, MCE, USA), 1‰ H2O2, 200 μg/ml LPS (HY-D1056, MCE, USA), and 300 nM rapamycin (HY-10219, MCE, USA) for 24 h. Cell viability was assessed 24 h later by CCK-8.

    Article Title: Bladder cancer selective chemotherapy with potent NQO1 substrate co-loaded prodrug nanoparticles.
    Article Snippet: Currently, clinical intravesical instillation chemotherapy has been greatly compromised by the toxicological and physiological factors.. New formulations that can specifically and efficiently kill bladder cancer cells are in urgent need to overcome the low residence efficiency and dose limiting toxicity of current ones.. The combination of mucoadhesive nanocarriers and cancer cell selective prodrugs can to great extent address these limitations.

    Western Blot:


    Article Title: RNA binding protein NKAP protects glioblastoma cells from ferroptosis by promoting SLC7A11 mRNA splicing in an m 6 A-dependent manner
    Article Snippet: Each group of cells were treated with compounds including 10 μM erastin (HY-15763, MCE, USA), 100 μM iFSP1 (HY-136057, MCE, USA), 500 μM SAS (HY-14655, MCE, USA), 2.5 μM rotenone (HY-B1756, MCE, USA), 300 nM 17-DMAG (HY-10389, MCE, USA), 1.5 μM staurosporine (HY-15141, MCE, USA), 200 μM TMZ (HY-17364, MCE, USA), 2 μM β-lapachone (HY-13555, MCE, USA), 1‰ H2O2, 200 μg/ml LPS (HY-D1056, MCE, USA), and 300 nM rapamycin (HY-10219, MCE, USA) for 24 h. Cell viability was assessed 24 h later by CCK-8.

    Article Title: Bladder cancer selective chemotherapy with potent NQO1 substrate co-loaded prodrug nanoparticles.
    Article Snippet: Currently, clinical intravesical instillation chemotherapy has been greatly compromised by the toxicological and physiological factors.. New formulations that can specifically and efficiently kill bladder cancer cells are in urgent need to overcome the low residence efficiency and dose limiting toxicity of current ones.. The combination of mucoadhesive nanocarriers and cancer cell selective prodrugs can to great extent address these limitations.

    MTT Assay:


    Article Title: RNA binding protein NKAP protects glioblastoma cells from ferroptosis by promoting SLC7A11 mRNA splicing in an m 6 A-dependent manner
    Article Snippet: Each group of cells were treated with compounds including 10 μM erastin (HY-15763, MCE, USA), 100 μM iFSP1 (HY-136057, MCE, USA), 500 μM SAS (HY-14655, MCE, USA), 2.5 μM rotenone (HY-B1756, MCE, USA), 300 nM 17-DMAG (HY-10389, MCE, USA), 1.5 μM staurosporine (HY-15141, MCE, USA), 200 μM TMZ (HY-17364, MCE, USA), 2 μM β-lapachone (HY-13555, MCE, USA), 1‰ H2O2, 200 μg/ml LPS (HY-D1056, MCE, USA), and 300 nM rapamycin (HY-10219, MCE, USA) for 24 h. Cell viability was assessed 24 h later by CCK-8.

    Article Title: Bladder cancer selective chemotherapy with potent NQO1 substrate co-loaded prodrug nanoparticles.
    Article Snippet: Currently, clinical intravesical instillation chemotherapy has been greatly compromised by the toxicological and physiological factors.. New formulations that can specifically and efficiently kill bladder cancer cells are in urgent need to overcome the low residence efficiency and dose limiting toxicity of current ones.. The combination of mucoadhesive nanocarriers and cancer cell selective prodrugs can to great extent address these limitations.

    Colony Assay:


    Article Title: RNA binding protein NKAP protects glioblastoma cells from ferroptosis by promoting SLC7A11 mRNA splicing in an m 6 A-dependent manner
    Article Snippet: Each group of cells were treated with compounds including 10 μM erastin (HY-15763, MCE, USA), 100 μM iFSP1 (HY-136057, MCE, USA), 500 μM SAS (HY-14655, MCE, USA), 2.5 μM rotenone (HY-B1756, MCE, USA), 300 nM 17-DMAG (HY-10389, MCE, USA), 1.5 μM staurosporine (HY-15141, MCE, USA), 200 μM TMZ (HY-17364, MCE, USA), 2 μM β-lapachone (HY-13555, MCE, USA), 1‰ H2O2, 200 μg/ml LPS (HY-D1056, MCE, USA), and 300 nM rapamycin (HY-10219, MCE, USA) for 24 h. Cell viability was assessed 24 h later by CCK-8.

    Article Title: Bladder cancer selective chemotherapy with potent NQO1 substrate co-loaded prodrug nanoparticles.
    Article Snippet: Currently, clinical intravesical instillation chemotherapy has been greatly compromised by the toxicological and physiological factors.. New formulations that can specifically and efficiently kill bladder cancer cells are in urgent need to overcome the low residence efficiency and dose limiting toxicity of current ones.. The combination of mucoadhesive nanocarriers and cancer cell selective prodrugs can to great extent address these limitations.

    Migration:


    Article Title: RNA binding protein NKAP protects glioblastoma cells from ferroptosis by promoting SLC7A11 mRNA splicing in an m 6 A-dependent manner
    Article Snippet: Each group of cells were treated with compounds including 10 μM erastin (HY-15763, MCE, USA), 100 μM iFSP1 (HY-136057, MCE, USA), 500 μM SAS (HY-14655, MCE, USA), 2.5 μM rotenone (HY-B1756, MCE, USA), 300 nM 17-DMAG (HY-10389, MCE, USA), 1.5 μM staurosporine (HY-15141, MCE, USA), 200 μM TMZ (HY-17364, MCE, USA), 2 μM β-lapachone (HY-13555, MCE, USA), 1‰ H2O2, 200 μg/ml LPS (HY-D1056, MCE, USA), and 300 nM rapamycin (HY-10219, MCE, USA) for 24 h. Cell viability was assessed 24 h later by CCK-8.

    Article Title: Bladder cancer selective chemotherapy with potent NQO1 substrate co-loaded prodrug nanoparticles.
    Article Snippet: Currently, clinical intravesical instillation chemotherapy has been greatly compromised by the toxicological and physiological factors.. New formulations that can specifically and efficiently kill bladder cancer cells are in urgent need to overcome the low residence efficiency and dose limiting toxicity of current ones.. The combination of mucoadhesive nanocarriers and cancer cell selective prodrugs can to great extent address these limitations.

    Wound Healing Assay:


    Article Title: RNA binding protein NKAP protects glioblastoma cells from ferroptosis by promoting SLC7A11 mRNA splicing in an m 6 A-dependent manner
    Article Snippet: Each group of cells were treated with compounds including 10 μM erastin (HY-15763, MCE, USA), 100 μM iFSP1 (HY-136057, MCE, USA), 500 μM SAS (HY-14655, MCE, USA), 2.5 μM rotenone (HY-B1756, MCE, USA), 300 nM 17-DMAG (HY-10389, MCE, USA), 1.5 μM staurosporine (HY-15141, MCE, USA), 200 μM TMZ (HY-17364, MCE, USA), 2 μM β-lapachone (HY-13555, MCE, USA), 1‰ H2O2, 200 μg/ml LPS (HY-D1056, MCE, USA), and 300 nM rapamycin (HY-10219, MCE, USA) for 24 h. Cell viability was assessed 24 h later by CCK-8.

    Article Title: Bladder cancer selective chemotherapy with potent NQO1 substrate co-loaded prodrug nanoparticles.
    Article Snippet: Currently, clinical intravesical instillation chemotherapy has been greatly compromised by the toxicological and physiological factors.. New formulations that can specifically and efficiently kill bladder cancer cells are in urgent need to overcome the low residence efficiency and dose limiting toxicity of current ones.. The combination of mucoadhesive nanocarriers and cancer cell selective prodrugs can to great extent address these limitations.

    Transwell Assay:


    Article Title: RNA binding protein NKAP protects glioblastoma cells from ferroptosis by promoting SLC7A11 mRNA splicing in an m 6 A-dependent manner
    Article Snippet: Each group of cells were treated with compounds including 10 μM erastin (HY-15763, MCE, USA), 100 μM iFSP1 (HY-136057, MCE, USA), 500 μM SAS (HY-14655, MCE, USA), 2.5 μM rotenone (HY-B1756, MCE, USA), 300 nM 17-DMAG (HY-10389, MCE, USA), 1.5 μM staurosporine (HY-15141, MCE, USA), 200 μM TMZ (HY-17364, MCE, USA), 2 μM β-lapachone (HY-13555, MCE, USA), 1‰ H2O2, 200 μg/ml LPS (HY-D1056, MCE, USA), and 300 nM rapamycin (HY-10219, MCE, USA) for 24 h. Cell viability was assessed 24 h later by CCK-8.

    Article Title: Bladder cancer selective chemotherapy with potent NQO1 substrate co-loaded prodrug nanoparticles.
    Article Snippet: Currently, clinical intravesical instillation chemotherapy has been greatly compromised by the toxicological and physiological factors.. New formulations that can specifically and efficiently kill bladder cancer cells are in urgent need to overcome the low residence efficiency and dose limiting toxicity of current ones.. The combination of mucoadhesive nanocarriers and cancer cell selective prodrugs can to great extent address these limitations.

    Tube Formation Assay:


    Article Title: RNA binding protein NKAP protects glioblastoma cells from ferroptosis by promoting SLC7A11 mRNA splicing in an m 6 A-dependent manner
    Article Snippet: Each group of cells were treated with compounds including 10 μM erastin (HY-15763, MCE, USA), 100 μM iFSP1 (HY-136057, MCE, USA), 500 μM SAS (HY-14655, MCE, USA), 2.5 μM rotenone (HY-B1756, MCE, USA), 300 nM 17-DMAG (HY-10389, MCE, USA), 1.5 μM staurosporine (HY-15141, MCE, USA), 200 μM TMZ (HY-17364, MCE, USA), 2 μM β-lapachone (HY-13555, MCE, USA), 1‰ H2O2, 200 μg/ml LPS (HY-D1056, MCE, USA), and 300 nM rapamycin (HY-10219, MCE, USA) for 24 h. Cell viability was assessed 24 h later by CCK-8.

    Article Title: Bladder cancer selective chemotherapy with potent NQO1 substrate co-loaded prodrug nanoparticles.
    Article Snippet: Currently, clinical intravesical instillation chemotherapy has been greatly compromised by the toxicological and physiological factors.. New formulations that can specifically and efficiently kill bladder cancer cells are in urgent need to overcome the low residence efficiency and dose limiting toxicity of current ones.. The combination of mucoadhesive nanocarriers and cancer cell selective prodrugs can to great extent address these limitations.

    Binding Assay:


    Article Title: RNA binding protein NKAP protects glioblastoma cells from ferroptosis by promoting SLC7A11 mRNA splicing in an m 6 A-dependent manner
    Article Snippet: Each group of cells were treated with compounds including 10 μM erastin (HY-15763, MCE, USA), 100 μM iFSP1 (HY-136057, MCE, USA), 500 μM SAS (HY-14655, MCE, USA), 2.5 μM rotenone (HY-B1756, MCE, USA), 300 nM 17-DMAG (HY-10389, MCE, USA), 1.5 μM staurosporine (HY-15141, MCE, USA), 200 μM TMZ (HY-17364, MCE, USA), 2 μM β-lapachone (HY-13555, MCE, USA), 1‰ H2O2, 200 μg/ml LPS (HY-D1056, MCE, USA), and 300 nM rapamycin (HY-10219, MCE, USA) for 24 h. Cell viability was assessed 24 h later by CCK-8.

    Article Title: Bladder cancer selective chemotherapy with potent NQO1 substrate co-loaded prodrug nanoparticles.
    Article Snippet: Currently, clinical intravesical instillation chemotherapy has been greatly compromised by the toxicological and physiological factors.. New formulations that can specifically and efficiently kill bladder cancer cells are in urgent need to overcome the low residence efficiency and dose limiting toxicity of current ones.. The combination of mucoadhesive nanocarriers and cancer cell selective prodrugs can to great extent address these limitations.

    Transfection:


    Article Title: RNA binding protein NKAP protects glioblastoma cells from ferroptosis by promoting SLC7A11 mRNA splicing in an m 6 A-dependent manner
    Article Snippet: Each group of cells were treated with compounds including 10 μM erastin (HY-15763, MCE, USA), 100 μM iFSP1 (HY-136057, MCE, USA), 500 μM SAS (HY-14655, MCE, USA), 2.5 μM rotenone (HY-B1756, MCE, USA), 300 nM 17-DMAG (HY-10389, MCE, USA), 1.5 μM staurosporine (HY-15141, MCE, USA), 200 μM TMZ (HY-17364, MCE, USA), 2 μM β-lapachone (HY-13555, MCE, USA), 1‰ H2O2, 200 μg/ml LPS (HY-D1056, MCE, USA), and 300 nM rapamycin (HY-10219, MCE, USA) for 24 h. Cell viability was assessed 24 h later by CCK-8.

    Article Title: Bladder cancer selective chemotherapy with potent NQO1 substrate co-loaded prodrug nanoparticles.
    Article Snippet: Currently, clinical intravesical instillation chemotherapy has been greatly compromised by the toxicological and physiological factors.. New formulations that can specifically and efficiently kill bladder cancer cells are in urgent need to overcome the low residence efficiency and dose limiting toxicity of current ones.. The combination of mucoadhesive nanocarriers and cancer cell selective prodrugs can to great extent address these limitations.

    Control:


    Article Title: RNA binding protein NKAP protects glioblastoma cells from ferroptosis by promoting SLC7A11 mRNA splicing in an m 6 A-dependent manner
    Article Snippet: Each group of cells were treated with compounds including 10 μM erastin (HY-15763, MCE, USA), 100 μM iFSP1 (HY-136057, MCE, USA), 500 μM SAS (HY-14655, MCE, USA), 2.5 μM rotenone (HY-B1756, MCE, USA), 300 nM 17-DMAG (HY-10389, MCE, USA), 1.5 μM staurosporine (HY-15141, MCE, USA), 200 μM TMZ (HY-17364, MCE, USA), 2 μM β-lapachone (HY-13555, MCE, USA), 1‰ H2O2, 200 μg/ml LPS (HY-D1056, MCE, USA), and 300 nM rapamycin (HY-10219, MCE, USA) for 24 h. Cell viability was assessed 24 h later by CCK-8.

    Article Title: Bladder cancer selective chemotherapy with potent NQO1 substrate co-loaded prodrug nanoparticles.
    Article Snippet: Currently, clinical intravesical instillation chemotherapy has been greatly compromised by the toxicological and physiological factors.. New formulations that can specifically and efficiently kill bladder cancer cells are in urgent need to overcome the low residence efficiency and dose limiting toxicity of current ones.. The combination of mucoadhesive nanocarriers and cancer cell selective prodrugs can to great extent address these limitations.

    Knockdown:


    Article Title: RNA binding protein NKAP protects glioblastoma cells from ferroptosis by promoting SLC7A11 mRNA splicing in an m 6 A-dependent manner
    Article Snippet: Each group of cells were treated with compounds including 10 μM erastin (HY-15763, MCE, USA), 100 μM iFSP1 (HY-136057, MCE, USA), 500 μM SAS (HY-14655, MCE, USA), 2.5 μM rotenone (HY-B1756, MCE, USA), 300 nM 17-DMAG (HY-10389, MCE, USA), 1.5 μM staurosporine (HY-15141, MCE, USA), 200 μM TMZ (HY-17364, MCE, USA), 2 μM β-lapachone (HY-13555, MCE, USA), 1‰ H2O2, 200 μg/ml LPS (HY-D1056, MCE, USA), and 300 nM rapamycin (HY-10219, MCE, USA) for 24 h. Cell viability was assessed 24 h later by CCK-8.

    Article Title: Bladder cancer selective chemotherapy with potent NQO1 substrate co-loaded prodrug nanoparticles.
    Article Snippet: Currently, clinical intravesical instillation chemotherapy has been greatly compromised by the toxicological and physiological factors.. New formulations that can specifically and efficiently kill bladder cancer cells are in urgent need to overcome the low residence efficiency and dose limiting toxicity of current ones.. The combination of mucoadhesive nanocarriers and cancer cell selective prodrugs can to great extent address these limitations.

    In Vivo:


    Article Title: RNA binding protein NKAP protects glioblastoma cells from ferroptosis by promoting SLC7A11 mRNA splicing in an m 6 A-dependent manner
    Article Snippet: Each group of cells were treated with compounds including 10 μM erastin (HY-15763, MCE, USA), 100 μM iFSP1 (HY-136057, MCE, USA), 500 μM SAS (HY-14655, MCE, USA), 2.5 μM rotenone (HY-B1756, MCE, USA), 300 nM 17-DMAG (HY-10389, MCE, USA), 1.5 μM staurosporine (HY-15141, MCE, USA), 200 μM TMZ (HY-17364, MCE, USA), 2 μM β-lapachone (HY-13555, MCE, USA), 1‰ H2O2, 200 μg/ml LPS (HY-D1056, MCE, USA), and 300 nM rapamycin (HY-10219, MCE, USA) for 24 h. Cell viability was assessed 24 h later by CCK-8.

    Article Title: Bladder cancer selective chemotherapy with potent NQO1 substrate co-loaded prodrug nanoparticles.
    Article Snippet: Currently, clinical intravesical instillation chemotherapy has been greatly compromised by the toxicological and physiological factors.. New formulations that can specifically and efficiently kill bladder cancer cells are in urgent need to overcome the low residence efficiency and dose limiting toxicity of current ones.. The combination of mucoadhesive nanocarriers and cancer cell selective prodrugs can to great extent address these limitations.

    Immunohistochemical staining:


    Article Title: RNA binding protein NKAP protects glioblastoma cells from ferroptosis by promoting SLC7A11 mRNA splicing in an m 6 A-dependent manner
    Article Snippet: Each group of cells were treated with compounds including 10 μM erastin (HY-15763, MCE, USA), 100 μM iFSP1 (HY-136057, MCE, USA), 500 μM SAS (HY-14655, MCE, USA), 2.5 μM rotenone (HY-B1756, MCE, USA), 300 nM 17-DMAG (HY-10389, MCE, USA), 1.5 μM staurosporine (HY-15141, MCE, USA), 200 μM TMZ (HY-17364, MCE, USA), 2 μM β-lapachone (HY-13555, MCE, USA), 1‰ H2O2, 200 μg/ml LPS (HY-D1056, MCE, USA), and 300 nM rapamycin (HY-10219, MCE, USA) for 24 h. Cell viability was assessed 24 h later by CCK-8.

    Article Title: Bladder cancer selective chemotherapy with potent NQO1 substrate co-loaded prodrug nanoparticles.
    Article Snippet: Currently, clinical intravesical instillation chemotherapy has been greatly compromised by the toxicological and physiological factors.. New formulations that can specifically and efficiently kill bladder cancer cells are in urgent need to overcome the low residence efficiency and dose limiting toxicity of current ones.. The combination of mucoadhesive nanocarriers and cancer cell selective prodrugs can to great extent address these limitations.

    Staining:


    Article Title: RNA binding protein NKAP protects glioblastoma cells from ferroptosis by promoting SLC7A11 mRNA splicing in an m 6 A-dependent manner
    Article Snippet: Each group of cells were treated with compounds including 10 μM erastin (HY-15763, MCE, USA), 100 μM iFSP1 (HY-136057, MCE, USA), 500 μM SAS (HY-14655, MCE, USA), 2.5 μM rotenone (HY-B1756, MCE, USA), 300 nM 17-DMAG (HY-10389, MCE, USA), 1.5 μM staurosporine (HY-15141, MCE, USA), 200 μM TMZ (HY-17364, MCE, USA), 2 μM β-lapachone (HY-13555, MCE, USA), 1‰ H2O2, 200 μg/ml LPS (HY-D1056, MCE, USA), and 300 nM rapamycin (HY-10219, MCE, USA) for 24 h. Cell viability was assessed 24 h later by CCK-8.

    Article Title: Bladder cancer selective chemotherapy with potent NQO1 substrate co-loaded prodrug nanoparticles.
    Article Snippet: Currently, clinical intravesical instillation chemotherapy has been greatly compromised by the toxicological and physiological factors.. New formulations that can specifically and efficiently kill bladder cancer cells are in urgent need to overcome the low residence efficiency and dose limiting toxicity of current ones.. The combination of mucoadhesive nanocarriers and cancer cell selective prodrugs can to great extent address these limitations.

    Droplet Countercurrent Chromatography:


    Article Title: RNA binding protein NKAP protects glioblastoma cells from ferroptosis by promoting SLC7A11 mRNA splicing in an m 6 A-dependent manner
    Article Snippet: Each group of cells were treated with compounds including 10 μM erastin (HY-15763, MCE, USA), 100 μM iFSP1 (HY-136057, MCE, USA), 500 μM SAS (HY-14655, MCE, USA), 2.5 μM rotenone (HY-B1756, MCE, USA), 300 nM 17-DMAG (HY-10389, MCE, USA), 1.5 μM staurosporine (HY-15141, MCE, USA), 200 μM TMZ (HY-17364, MCE, USA), 2 μM β-lapachone (HY-13555, MCE, USA), 1‰ H2O2, 200 μg/ml LPS (HY-D1056, MCE, USA), and 300 nM rapamycin (HY-10219, MCE, USA) for 24 h. Cell viability was assessed 24 h later by CCK-8.

    Article Title: Bladder cancer selective chemotherapy with potent NQO1 substrate co-loaded prodrug nanoparticles.
    Article Snippet: Currently, clinical intravesical instillation chemotherapy has been greatly compromised by the toxicological and physiological factors.. New formulations that can specifically and efficiently kill bladder cancer cells are in urgent need to overcome the low residence efficiency and dose limiting toxicity of current ones.. The combination of mucoadhesive nanocarriers and cancer cell selective prodrugs can to great extent address these limitations.

    Purification:


    Article Title: RNA binding protein NKAP protects glioblastoma cells from ferroptosis by promoting SLC7A11 mRNA splicing in an m 6 A-dependent manner
    Article Snippet: Each group of cells were treated with compounds including 10 μM erastin (HY-15763, MCE, USA), 100 μM iFSP1 (HY-136057, MCE, USA), 500 μM SAS (HY-14655, MCE, USA), 2.5 μM rotenone (HY-B1756, MCE, USA), 300 nM 17-DMAG (HY-10389, MCE, USA), 1.5 μM staurosporine (HY-15141, MCE, USA), 200 μM TMZ (HY-17364, MCE, USA), 2 μM β-lapachone (HY-13555, MCE, USA), 1‰ H2O2, 200 μg/ml LPS (HY-D1056, MCE, USA), and 300 nM rapamycin (HY-10219, MCE, USA) for 24 h. Cell viability was assessed 24 h later by CCK-8.

    Article Title: Bladder cancer selective chemotherapy with potent NQO1 substrate co-loaded prodrug nanoparticles.
    Article Snippet: Currently, clinical intravesical instillation chemotherapy has been greatly compromised by the toxicological and physiological factors.. New formulations that can specifically and efficiently kill bladder cancer cells are in urgent need to overcome the low residence efficiency and dose limiting toxicity of current ones.. The combination of mucoadhesive nanocarriers and cancer cell selective prodrugs can to great extent address these limitations.



    Similar Products

    90
    TargetMol β-lapachone
    β Lapachone, supplied by TargetMol, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/%CE%B2+lapachone/%CE%B2-Lapachone/targetmol___t6407
    Average 90 stars, based on 1 article reviews
    β-lapachone - by Bioz Stars, 2026-11
    90/100 stars
      Buy from Supplier

    94
    MedChemExpress β lapachone
    β Lapachone, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/%CE%B2+lapachone/%CE%B2-Lapachone/pm40103499-253-6-10
    Average 94 stars, based on 1 article reviews
    β lapachone - by Bioz Stars, 2026-11
    94/100 stars
      Buy from Supplier

    86
    Molecular Dynamics Inc β lapachone
    β Lapachone, supplied by Molecular Dynamics Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/%CE%B2+lapachone/lapachone+%CE%B2/pm42154529-603-50-22
    Average 86 stars, based on 1 article reviews
    β lapachone - by Bioz Stars, 2026-11
    86/100 stars
      Buy from Supplier

    86
    Nanotherapeutics β lapachone
    β Lapachone, supplied by Nanotherapeutics, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/%CE%B2+lapachone/containing+lapachone+%CE%B2/pm42151631-1302-4-10
    Average 86 stars, based on 1 article reviews
    β lapachone - by Bioz Stars, 2026-11
    86/100 stars
      Buy from Supplier

    86
    Nanotherapeutics d a β lapachone micellar nanotherapeutics
    D A β Lapachone Micellar Nanotherapeutics, supplied by Nanotherapeutics, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/%CE%B2+lapachone/a+d+lapachone+micellar+nanotherapeutics+%CE%B2/pm42050554-308-29-33
    Average 86 stars, based on 1 article reviews
    d a β lapachone micellar nanotherapeutics - by Bioz Stars, 2026-11
    86/100 stars
      Buy from Supplier

    90
    Millipore β-lapachone
    β Lapachone, supplied by Millipore, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/%CE%B2+lapachone/%CE%B2+lapachone/pm40540400-779-257-259
    Average 90 stars, based on 1 article reviews
    β-lapachone - by Bioz Stars, 2026-11
    90/100 stars
      Buy from Supplier

    90
    Macklin Inc β –lapachone β –lap
    Schematic illustration of IR783‐stabilized nanodrugs to enhance anticancer immune response and promote breast cancer immunotherapy. A) The nanodrugs are formulated with IR783, β ‐lap, and CUDC101. IR783 serves as a stabilizer to form nanoparticles with two hydrophobic drug molecules based on small molecule self‐assembly. B) The nanodrugs can enter breast cancer cells through CAV‐1‐mediated endocytosis pathway and achieve synergistic anticancer effects from NQO1‐dependent oxidation therapy and CUDC101‐provoked epigenetic regulation. C) The nanodrugs can further promote DAMPs release and dendritic cell maturation to boost systemic antitumor immunity and inhibit both primary and distant tumor growth.
    β –Lapachone β –Lap, supplied by Macklin Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/%CE%B2+lapachone/%CE%B2++lapachone+%CE%B2++lap/pmc12140360-218-0-13
    Average 90 stars, based on 1 article reviews
    β –lapachone β –lap - by Bioz Stars, 2026-11
    90/100 stars
      Buy from Supplier

    90
    BioMimetic Therapeutics β-lapachone (lapa)
    Schematic illustration of IR783‐stabilized nanodrugs to enhance anticancer immune response and promote breast cancer immunotherapy. A) The nanodrugs are formulated with IR783, β ‐lap, and CUDC101. IR783 serves as a stabilizer to form nanoparticles with two hydrophobic drug molecules based on small molecule self‐assembly. B) The nanodrugs can enter breast cancer cells through CAV‐1‐mediated endocytosis pathway and achieve synergistic anticancer effects from NQO1‐dependent oxidation therapy and CUDC101‐provoked epigenetic regulation. C) The nanodrugs can further promote DAMPs release and dendritic cell maturation to boost systemic antitumor immunity and inhibit both primary and distant tumor growth.
    β Lapachone (Lapa), supplied by BioMimetic Therapeutics, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/%CE%B2+lapachone/%CE%B2+lapachone++lapa+/pm39742839-3-8-29
    Average 90 stars, based on 1 article reviews
    β-lapachone (lapa) - by Bioz Stars, 2026-11
    90/100 stars
      Buy from Supplier

    Image Search Results


    Schematic illustration of IR783‐stabilized nanodrugs to enhance anticancer immune response and promote breast cancer immunotherapy. A) The nanodrugs are formulated with IR783, β ‐lap, and CUDC101. IR783 serves as a stabilizer to form nanoparticles with two hydrophobic drug molecules based on small molecule self‐assembly. B) The nanodrugs can enter breast cancer cells through CAV‐1‐mediated endocytosis pathway and achieve synergistic anticancer effects from NQO1‐dependent oxidation therapy and CUDC101‐provoked epigenetic regulation. C) The nanodrugs can further promote DAMPs release and dendritic cell maturation to boost systemic antitumor immunity and inhibit both primary and distant tumor growth.

    Journal: Advanced Science

    Article Title: IR783‐Stabilized Nanodrugs Enhance Anticancer Immune Response by Synergizing Oxidation Therapy and Epigenetic Modulation

    doi: 10.1002/advs.202415684

    Figure Lengend Snippet: Schematic illustration of IR783‐stabilized nanodrugs to enhance anticancer immune response and promote breast cancer immunotherapy. A) The nanodrugs are formulated with IR783, β ‐lap, and CUDC101. IR783 serves as a stabilizer to form nanoparticles with two hydrophobic drug molecules based on small molecule self‐assembly. B) The nanodrugs can enter breast cancer cells through CAV‐1‐mediated endocytosis pathway and achieve synergistic anticancer effects from NQO1‐dependent oxidation therapy and CUDC101‐provoked epigenetic regulation. C) The nanodrugs can further promote DAMPs release and dendritic cell maturation to boost systemic antitumor immunity and inhibit both primary and distant tumor growth.

    Article Snippet: β ‐lapachone ( β ‐lap), crystal violet, and DNase I were obtained from Macklin (Shanghai, China).

    Techniques:

    Preparation and characterization of IR/Lap/CUDC NPs. A) Size distribution and transmission electron microscopy (TEM) image of IR/Lap/CUDC NPs (Scale bar: 200 nm). B) Zeta potential of IR/Lap/CUDC NPs. C) UV–vis absorption spectra of free β ‐lap, CUDC101, IR783, and IR/Lap/CUDC NPs. D) Stability test of IR/Lap/CUDC NPs under physiological conditions for 48 h. E) Size distribution changes of IR/Lap/CUDC NPs after H 2 O 2 incubation. F) Fluorescent spectra of IR/Lap/CUDC NPs with or without H 2 O 2 incubation. G) UV–vis absorption spectra of IR/Lap/CUDC NPs with or without H 2 O 2 incubation. H) Cell viability of 4T1 cells treated with gradient concentrations of free β ‐lap and CUDC101. I) Synergy score of free β ‐lap and CUDC101 in 4T1 cells at gradient concentrations calculated by the Highest Single Agent (HSA) model in SynergyFinder.

    Journal: Advanced Science

    Article Title: IR783‐Stabilized Nanodrugs Enhance Anticancer Immune Response by Synergizing Oxidation Therapy and Epigenetic Modulation

    doi: 10.1002/advs.202415684

    Figure Lengend Snippet: Preparation and characterization of IR/Lap/CUDC NPs. A) Size distribution and transmission electron microscopy (TEM) image of IR/Lap/CUDC NPs (Scale bar: 200 nm). B) Zeta potential of IR/Lap/CUDC NPs. C) UV–vis absorption spectra of free β ‐lap, CUDC101, IR783, and IR/Lap/CUDC NPs. D) Stability test of IR/Lap/CUDC NPs under physiological conditions for 48 h. E) Size distribution changes of IR/Lap/CUDC NPs after H 2 O 2 incubation. F) Fluorescent spectra of IR/Lap/CUDC NPs with or without H 2 O 2 incubation. G) UV–vis absorption spectra of IR/Lap/CUDC NPs with or without H 2 O 2 incubation. H) Cell viability of 4T1 cells treated with gradient concentrations of free β ‐lap and CUDC101. I) Synergy score of free β ‐lap and CUDC101 in 4T1 cells at gradient concentrations calculated by the Highest Single Agent (HSA) model in SynergyFinder. "NPs" shown in (E), (F), and (G) refers to IR/Lap/CUDC NPs.

    Article Snippet: β ‐lapachone ( β ‐lap), crystal violet, and DNase I were obtained from Macklin (Shanghai, China).

    Techniques: Transmission Assay, Electron Microscopy, Zeta Potential Analyzer, Incubation